3 research outputs found

    Hospitalizations for infections in primary Sjögren’s syndrome patients: a nationwide incidence study

    No full text
    Primary Sjögren’s syndrome (pSS) is an autoimmune disease with increased risk of infections. Here, we assessed whether pSS patients were at higher risk of hospitalization for community and opportunistic infections. We selected newly hospitalized pSS patients between 2011 and 2018, through a nationwide population-based retrospective study using the French Health insurance database. We compared the incidence of hospitalization for several types of infections (according to International Classification for Disease codes, ICD-10) between pSS patients and an age- and sex-matched (1:10) hospitalized control group. We calculated adjusted Hazard Ratios (aHR, 95% CI) adjusted on socio-economic status, past cardiovascular or lung diseases and blood malignancies factors. We compared 25 661 pSS patients with 252 543 matched patients. The incidence of hospitalizations for a first community infection was increased in pSS patients [aHR of 1.29 (1.22–1.31), p p p p p p = .011 and 2.54 (1.27–5.06), p = .008, respectively]. pSS patients are at higher risk of hospitalization for infections. The increased risk of hospitalization for mycobacterial infections illustrates the potential bilateral relationship between the two conditions. Vaccination against respiratory pathogens and herpes zoster virus may help prevent some hospitalizations in pSS patients.KEY MESSAGESPrimary Sjögren’s syndrome (pSS) increases hospitalization risk for community infections: bronchopulmonary, skin, dental, ear–nose–throat, intestinal infections and pyelonephritis.Hospitalizations for zoster and mycobacterial infections are also increased in this population.Dedicated preventive measures and vaccination campaigns could decrease the burden of infections in pSS patients. Primary Sjögren’s syndrome (pSS) increases hospitalization risk for community infections: bronchopulmonary, skin, dental, ear–nose–throat, intestinal infections and pyelonephritis. Hospitalizations for zoster and mycobacterial infections are also increased in this population. Dedicated preventive measures and vaccination campaigns could decrease the burden of infections in pSS patients.</p

    Immunofluorescence staining of neutrophils by anti-PTX3 Abs.

    No full text
    <p>Slides containing 4 biochips as substrate ethanol-fixed (upper left), formol-aceton fixed neutrophils (upper right) methanol-fixed neutrophils (lower left) and HEp2 cells (lower right) were incubated with <b>A</b>, a serum from a patient with anti-PTX3 aAbs and neither MPO, PR3, BPI, lactoferrine, elastase nor cathepsin G ANCA, <b>B</b>, an anti-PTX3 polyclonal antibody or <b>C-E</b>, control sera for p-ANCA (<b>C</b>), a-ANCA (<b>D)</b>, c-ANCA (<b>E</b>). <b>A, C-E</b>, results are representative of the results obtained with one out of four sera. B, Results are representative of one out of three experiments.</p

    Longitudinal analysis of anti-PTX3 aAbs.

    No full text
    <p>Anti-PTX3 aAbs were analysed by ELISA in 14 patients with active disease (onset or relapse) and at remission. Results are expressed in OD values. Dotted line corresponds to mean + 2 SD titres of anti-PTX3 aAbs in HS sera; full line corresponds to the mean OD in each group of patients. Each line represents one patient. *p<0.05.</p
    corecore